Hahn Capital Management LLC raised its stake in Becton Dickinson and Co (NYSE:BDX) by 1.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 217,342 shares of the medical instruments supplier’s stock after acquiring an additional 2,055 shares during the period. Becton Dickinson and comprises about 4.2% of Hahn Capital Management LLC’s investment portfolio, making the stock its 3rd largest position. Hahn Capital Management LLC owned 0.10% of Becton Dickinson and worth $42,588,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently made changes to their positions in the company. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in Becton Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 240 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in Becton Dickinson and by 8.1% in the second quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock worth $133,000 after purchasing an additional 51 shares in the last quarter. Harfst & Associates Inc. boosted its stake in Becton Dickinson and by 46.4% in the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after purchasing an additional 221 shares in the last quarter. Harvest Fund Management Co. Ltd boosted its stake in Becton Dickinson and by 82.8% in the second quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock worth $146,000 after purchasing an additional 338 shares in the last quarter. Finally, Acrospire Investment Management LLC boosted its stake in Becton Dickinson and by 259.7% in the second quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock worth $162,000 after purchasing an additional 600 shares in the last quarter. Hedge funds and other institutional investors own 88.60% of the company’s stock.

A number of equities analysts have commented on the company. Argus boosted their price objective on Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research note on Thursday. They noted that the move was a valuation call. Stifel Nicolaus reissued a “buy” rating and issued a $245.00 price objective on shares of Becton Dickinson and in a research note on Friday, November 3rd. Morgan Stanley boosted their price objective on Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Royal Bank of Canada reissued a “sector perform” rating and issued a $230.00 price objective (up previously from $210.00) on shares of Becton Dickinson and in a research note on Friday, November 3rd. Finally, Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price objective on the stock in a research note on Tuesday, October 31st. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $218.36.

Becton Dickinson and Co (BDX) opened at $218.77 on Friday. The stock has a market capitalization of $49,913.57, a price-to-earnings ratio of 23.07, a PEG ratio of 1.71 and a beta of 1.07. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58. Becton Dickinson and Co has a one year low of $161.50 and a one year high of $229.68.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. The business had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The firm’s revenue was down 2.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.12 earnings per share. analysts forecast that Becton Dickinson and Co will post 10.63 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be issued a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.37%. The ex-dividend date is Thursday, December 7th. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.73. Becton Dickinson and’s dividend payout ratio is currently 64.52%.

TRADEMARK VIOLATION NOTICE: “Becton Dickinson and Co (BDX) is Hahn Capital Management LLC’s 3rd Largest Position” was first published by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.dailypolitical.com/2017/12/15/becton-dickinson-and-co-bdx-is-hahn-capital-management-llcs-3rd-largest-position.html.

Becton Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.